跳至主要内容
临床试验/ISRCTN96068143
ISRCTN96068143已完成Unknown

Evaluation of the efficacy of a food supplement based on probiotics, vitamin PP and vitamin B2 in improving heartburn symptom/dyspeptic disorders and heartburn-related quality of life in subjects with mild to moderate gastroesophageal reflux disease (GERD): a randomized, double-blind, placebo-controlled clinical study

utratech Srl0 个研究点目标入组 56 人开始时间: 2024年1月31日最近更新:

试验速览

阶段
Unknown
状态
已完成
发起方
入组人数
56

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Healthy male and female subjects aged 18 to 50 years old (inclusive), aware of the study procedures and having signed an informed consent form
  • 2. Subjects who experienced mild or moderate heartburn according to Dyspepsia questionnaire (modified Leeds card)
  • 3. Subjects used over-the-counter (OTC) products for heartburn, food supplements, or dietary manipulation to relieve heartburn symptoms during the previous 3 months
  • 4. Willingness not to use products apart from the product tested throughout the study period and antiacids**
  • 5. Willingness not to vary the normal daily routine (i.e. lifestyle, physical activity, usual diet, fluid intake etc)
  • 6. Subjects under effective contraception (oral/not oral) therapy
  • 7. Available and willing to follow the procedure of the study protocol
  • 8. Subjects who have not been recently involved in any other similar study (at least 2 months of wash-out)
  • 9. Subjects registered with the National Health Service (NHS)
  • 10. Willingness to respect the instructions given by the investigator as well as to respect the study constraints and specific requirements
  • 11. The pharmacological therapy (except for the pharmacological therapy in the non-inclusion criteria) should be stable for at least 1 month without any changes expected or planned during the study

排除标准

  • 1. Subjects not fulfilling the inclusion criteria above
  • 2. Alimentary/eating disorders (i.e. bulimia, psychogenic eating disorders, etc)
  • 3. Severe heartburn problem during the week prior to the study
  • 4. Previous or current treatment for any gastrointestinal diseases or illnesses
  • 5. Diagnosis of Barrett’s esophagus
  • 6. Previous upper gastrointestinal surgery
  • 7. Clinically significant GI bleeding within the last 3 months
  • 8. Esophagitis not related to acid reflux
  • 9. Known hypersensitivity or allergy to one of the active ingredients
  • 10. Bleeding disorder, Zollinger–Ellison Syndrome, duodenal/gastric ulcer and upper gastrointestinal malignancy
  • 11. Alcohol or drug abuse
  • 12. Under pharmacological treatments (abuse of FANS, antibiotics, etc) known to interfere with the tested product
  • 13. Clinical history with relevant presence of any disorder or administration of drugs/food supplement that can potentially interfere with the treatment under study
  • 14. Pregnant or breastfeeding women
  • 15. Known food intolerance or food allergy
  • 16. Unstable medical diseases (cardiac arrhythmias or ischemia, uncontrolled hypertension and hypotension, diabetes mellitus, kidney failure)
  • 17. History of paralysis or cerebral vascular accident
  • 18. Subjects participating or planning to participate in other clinical trials
  • 19. Adult protected by the law (under guardianship, or hospitalized in a public or private institution, for a reason other than the research, or incarcerated)

研究者

发起方
utratech Srl

相似试验